Baethge C, Baldessarini RJ, Mathiske-Schmidt K, Hennen J, Berghofer A, Muller-Oerlinghausen B, Bschor T, Adli M, Bauer M. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 2005;66:174-182
Baethge C, Gruschka P, Berghoefer A, Bauer M, Mueller-Oerlinghausen B, Bschor T, Smolka MN. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. J Affect Disord 2004;79:43-50
Baethge C, Gruschka P, Smolka MN, Berghöfer A, Bschor T, Müller-Oerlinghausen B, Bauer M. Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder. J Psychiatry Neurosci 2003;28:355-361
Baethge C, Smolka MN, Gruschka P, Berghöfer A, Schlattmann P, Bauer M, Altshuler L, Grof P, Müller-Oerlinghausen B. Does prophylaxis delay in bipolar disorders influence outcome? Results from a long-term study of 147 patients. Acta Psychiatr Scand 2003:107:260-267
Baethge C, Tondo L, Bratti IM, Bschor T, Bauer M, Viguera MC, Baldessarini RJ. Prophylaxis-latency and outcome in bipolar disorders. Can J Psychiatry 2003;48:449-457
Bauer M, Glenn T, Grof P, Pfennig A, Rasgon NL, Marsh W, Munoz RA, Sagduyu K, Alda M, Quiroz D, Sasse J, Whybrow PC. Self-reported data from patients with bipolar disorder: Frequency of brief depression. J Affect Disord. 2007;101:227-233
Bauer M, Rasgon N, Grof P, Glenn T, Lapp M, Marsh W, Munoz R, Suwalska A, Baethge C, Bschor T, Alda M, Whybrow PC. Do antidepressants influence mood patterns? A naturalistic study in bipolar disorder. Eur Psychiatry 2006;21:262-269
Bauer M, Grof P, Rasgon NL, Marsh W, Munoz RA, Sagduyu K, Alda M, Quiroz D, Glenn T, Baethge C, Whybrow PC. Self-reported data from patients with bipolar disorder: impact on minimum episode length for hypomania. J Affect Disord. 2006;96:101-105
Bauer M, Grof P, Gyulai L, Rasgon N, Glenn T, Whybrow PC. Using technology to improve longitudinal studies: self-reporting with ChronoRecord in bipolar disorder. Bipolar Disord 2004;6:67-74
Bauer M, Alda M, Priller J, Young LT; International Group For The Study Of Lithium Treated Patients (IGSLI) Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 2003;36 Suppl 3:S250-S254
Berghöfer A, Alda M, Adli M, Baethge C, Bauer M, Bschor T, Grof P, Müller-Oerlinghausen B, Rybakowski JK, Suwalska A, Pfennig A: Stability of lithium treatment in bipolar disorder – long-term follow-up of 346 patients. Int J Bip Disord 2013, 1:11, doi:10.1186/2194-7511-1-11
Berghöfer A, Müller-Oerlinghausen B. Is there a loss of efficacy of lithium in patients treated for over 20 years? Neuropsychobiology 2000;42(suppl.1):46-49
Berghöfer A, Müller-Oerlinghausen B. No loss of efficacy after discontinuation and reinstitution of long-term lithium treatment? In: Gallicchio VS, Birch NJ (eds.) Lithium. Biochemical and Clinical Advances. Weidner Publishing Group, Cheshire, Conn 1996,pp.39-46
Berghöfer A, Kossmann B, Müller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: A retrospective analysis over 15 years. Acta Psychiatr Scand 1996, 93, 349-354
Bernhard B, Schaub A, Kummler P, Dittmann S, Severus E, Seemuller F, Born C, Forsthoff A, Licht RW, Grunze H. Impact of cognitive-psychoeducational interventions in bipolar patients and their relatives. Eur Psychiatry 2006;21:81-86
Bieling PJ, MacQueen GM, Marriot MJ, Robb JC, Begin H, Joffe RT, Young LT. Longitudinal outcome in patients with bipolar disorder assessed by life-charting is influenced by DSM-IV personality disorder symptoms. Bipolar Disord 2003;5:14-21
Bratti IM, Baldessarini RJ, Baethge C, Tondo L: Pretreatment episode count and response to lithium treatment in manic-depressive illness. Harv. Rev. Psychiatry 2003; 11:245–56
Bschor T: Lithium in the Treatment of Major Depressive Disorder. Drugs 2014;74:855-862
Bschor T, Uhr M, Baethge C, Lewitzka U, Ising M, Erbe S, Winkelmann P, Ritter D: Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression. J Clin Psychopharmacol 2013;33:38-44
Deshauer D, Duffy A, Alda M, Grof E, Albuquerque J, Grof P. The cortisol awakening response in bipolar illness: a pilot study. Can J Psychiatry 2003;48:462-466
Deshauer D, Grof E, Alda M, Grof P: Patterns of DST positivity in remitted affective disorders. Biol Psychiatry 1999;45:1023-1029
Garnham J, Munro A, Slaney C, Macdougall M, Passmore M, Duffy A, O’Donovan C, Teehan A, Alda M. Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study. J Affect Disord 2007 Apr 16;
Glenn T, Whybrow PC, Rasgon N, Grof P, Alda M, Baethge C, Bauer M. Approximate entropy of self-reported mood prior to episodes in bipolar disorder. Bipolar Disord 2006;8(5 Pt 1):424-429
Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry 2003;64 (Suppl 5):53-61
Grof P, Robbins W, Alda M, Berghöfer A, Vojtechovsky M, Nilsson A, Robertson C. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord 2000;61:31-39
Grof P, Alda M. Discrepancies in the efficacy of lithium (letter to the editor). Arch Gen Psychiatry 2000;57:191
Grof P. Excellent lithium responders: People whose lives have been changed by lithium prophylaxis. In: Birch NJ, Gallicchio VS, Becker RW (eds.) Lithium: 50 years of psychopharmacology. New perspectives in biomedical and clinical research. Weidner, Cheshire 1999, pp.36-51
Grof P, Alda M, Ahrens B. Clinical course of affective disorders: were Emil Kraepelin and Jules Angst wrong? Psychopathology 1995;28 (Suppl 1):73-80
Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry 1993;21:16-19
Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA; LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry. 2003 Feb;64(2):144-51.
Kleindienst N, Severus WE, Greil W. Are serum levels related to the polarity of recurrence in bipolar disorders? Evidence form a multicenter trial. Int Clin Psychopharmacol 2007;22:125-131
Kleindienst N, Severus WE, Möller HJ, Greil W. Is polarity of recurrence related to serum lithium level in patients with bipolar disorder? Eur Arch Psychiaty Clin Neurosci 2005;255:72-74
Lewitzka U, Scheffczyk R, Ritter D, Doucette S, Bauer M, Bschor T: No correlation between lithium serum levels and psychopathological features during the euthymic interval of patients with recurrent affective disorder. Pharmacopsychiatry 2012;45:1-6
Licht RW, Vestergaard P, Rasmussen NA, Jepsen K, Brodersen A, Hansen PE. A lithium clinic for bipolar patients: 2-year outcome of the first 148 patients. Acta Psychiatr Scand 2001;104:387-390.
MacQueen GM, Marriott M, Begin H, Robb J, Joffe RT, Young LT. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord 2003;5:349-355
Nolen WA. More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment? Int J Bipolar Disord. 2015 Jan 31;3:1.
Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord. 2013 Feb;15(1):100-9.
Passmore MJ, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, Teehan A, Alda M. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003;5:110-114
Pfennig A, Schlattmann P, Alda M, Grof P, Glenn T, Müller-Oerlinghausen B, Suwalska A, Rybakowski J, Willich S N, Bauer M, Berghöfer A. Influence of atypical features on the quality of prophylactic effectiveness of long-term lithium treatment in bipolar disorders. Bipolar Disord 2010;12(4): 390-396
Rasgon N, Bauer M, Glenn T, Elman S, Whybrow PC. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord 2003;5:48-52
Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 2003;48:458-461
Rybakowski JK, Chlopocka-Wozniak M, Suwalska A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disord 2001;3:63-67
Rybakowski JK, Dyson WL, Amsterdam JD. Alexithymia and somatic conditions in patients with affective illnesses during lithium prophylaxis. Psychother Psychosom 1988;49:1-5
Rybakowski JK, Chlopocka-Wozniak M, Kapelski Z, Strzyzewski W. The relative prophylactic efficacy of lithium against manic and depressive recurrences in bipolar patients. Int Pharmacopsychiatry 1980;15:86-90
Schaub, R, Berghöfer A, Müller-Oerlinghausen B. What do patients in a lithium outpatient clinic know about lithium? J Psychiatry Neurosci 2001;26:319-324
Schumann C, Lenz G, Berghöfer A, Müller-Oerlinghausen B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatr Research 1999;89:247-257
Severus WE, Lipkovich IA, Licht RW, Young AH, Greil W, Ketter T, Deberdt W, Tohen M. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry 2010;25:443-449
Severus WE, Kleindienst N, Seemüller F, Frangou S, Möller HJ, Greil W. What ist he optimal serum lithium level in the long-term treatment of bipolar disorder- a review? Bipolar Disord 2008;10:231-237
Severus WE, Kleindienst N, Greil W. Re-evalutation of randomized controlled trials of lithium monotherapy. Bipolar Disord 2006;8:519-520
Severus WE, Grunze H, Kleindienst N, Frangou S, Moeller HJ. Ist he prophylactic antidepressant efficacy of lithium in bipolar I disorder dependent on study design and lithium level? J Clin Psychopharmacol 2005;25:457-462
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell’Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-1290
Van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden MS, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group.. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010 Sep;122(3):246-54.
Van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Feb;70(2):223-31.
Vestergaard P, Licht RW, Brodersen A, Rasmussen NA, Christensen H, Arngrim T, Gronvall B, Kristensen E, Poulstrup I, Wentzer Licht R. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatr Scand 1998;98:310-315
Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B; Trial 144 Study Investigators.. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011 Nov;72(11):1452-64.
Whybrow PC, Grof P, Gyulai L, Rasgon N, Glenn T, Bauer M. The electronic assessment of the longitudinal course of bipolar disorder: the ChronoRecord software. Pharmacopsychiatry 2003;36 Suppl 3:S244-S249
Wilting I, Heerdink ER, Mersch PP, den Boer JA, Egberts AC, Nolen WA. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study. Bipolar Disord. 2009 Jun;11(4):434-40.
Zakowska-Dabrowska T, Rybakowski J. Lithium-induced EEG changes: relation to lithium levels in serum and red blood cells. Acta Psychiatr Scand 1973;49:457-465
Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001;34:132-136
Ahrens B, Grof P, Möller HJ, Müller-Oerlinghausen B, Wolf T. Extended survival of patients on long-term lithium treatment. Can J Psychiatry 1995;40:241-246
Ahrens B, Müller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Vestergaard P, Wolf R, Möller HJ. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995;33:67-75
Ahrens B, Berghöfer A, Wolf T, Müller-Oerlinghausen B. Suicide attempts, age and duration of illness in recurrent affective disorders. J Affective Disord 1995;36:43-49
Ahrens B, Müller-Oerlinghausen B, Grof P. Length of lithium treatment needed to eliminate the high mortality of affective disorders. Br J Psychiatr 1993;163 (suppl.21):27-29
Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Arch Suicide Res 2005;9:279-300
Berghöfer A. Lithium and suicide. BMJ 2013;347: f4449
Berghöfer A. Research explained. Lithium in the prevention of suicide in mood disorders. updated systematic review and meta-analysis. Student BMJ 2013;21: f5578
Blüml V, Regier MD, Hlavin G, Rockett IRH, König F, Vyssoki B, Bschor T, Kapusta ND. Lithium in the public water supply and suicide mortality in Texas. J Psychiatr Res 2013;47:407-411
Blüml V, Helbich M, Mayr M, Turnwald R, Vyssoki B, Lewitzka U, Hartung S, Plener PL, Fegert JM, Kapusta ND
Antidepressant sales and regional variations of suicide mortality in Germany
J Psychiatr Res 2016 Dec 13;87:88-94. doi: 10.1016/j.jpsychires.2016.12.013. [Epub ahead of print]
Brodersen A, Licht RW, Vestergaard P, Olesen AV, Mortensen PB. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000;176:429-433
Bronisch T, Brunner J, Bondy B, Rujescu D, Bishof G, Heuser I, Muller-Oerlinghausen B, Hawellek B, Maier W, Rao ML, Felber W, Lewitzka U, Oehler J, Broocks A, Hohagen F, Lauterbach E. A multicenter study about neurobiology of suicidal behavior: design, development, and preliminary results. Arch Suicide Res 2005;9:19-26
de Lara CL, Dumais A, Rouleau G, Lesage A, Dumont M, Chawky N, Alda M, Benkelfat C, Turecki G. STin2 Variant and Family History of Suicide as Significant Predictors of Suicide Completion in Major Depression. Biol Psychiatry 2005 Aug 24; [Epub ahead of print]
Dumais A, Lesage AD, Alda M, Rouleau G, Dumont M, Chawky N, Roy M, Mann JJ, Benkelfat C, Turecki G. Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry 2005;162:2116-2124
Felber W. [Lithium prophylaxis and suicide prervention] In: M Wolfersdorf, WP Kaschka (eds). [Suicidality – The Biological Dimension]. Tropon-Symposium, Bd. X.. Berlin, Heidelberg, New York: Springer, 1995; 157-174 (german)
Felber W, Kyber A. Suicides and parasuicides throughout and out of lithium prophylaxis. In: B Müller-Oerlinghausen, A Berghöfer (eds): Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Stuttgart, New York: Thieme, 1994; 53-59 (german)
Kyber A, Felber W, König L. Does lithium prevent suicides and suicidal attempts? Pharmacopsychiat 1992;25:108
Lauterbach E, Felber W, Müller-Oerlinghausen B, Ahrens B, Bronisch T, Meyer T, Kilb B, Lewitzka U, Hawellek B, Quante A, Richter K, Broocks A, Hohagen F. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand 2008;118:469-479
Lauterbach E, Ahrens B, Felber W, Oerlinghausen BM, Kilb B, Bischof G, Heuser I, Werner P, Hawellek B, Maier W, Lewitzka U, Pogarell O, Hegerl U, Bronisch T, Richter K, Niklewski G, Broocks A, Hohagen F. Suicide prevention by lithium SUPLI–challenges of a multi-center prospective study. Arch Suicide Res 2005;9:27-34
Lewitzka U, Jabs B, Fülle M, Holthoff V, Juckel G, Uhl I, Kittel-Schneider S, Reif A, Reif-Leonhard C, Gruber O, Djawid B, Goodday S, Haussmann R, Pfennig A, Ritter P, Conell J, Severus E, Bauer M. Does lithium reduce acute suicidal ideation and behavior? A protocol for a randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) in patients with suicidal major depressive episode. BMC Psychiatry. 2015 May 19;15:117
Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M. The suicide prevention effect of lithium: more than 20 years of evidence – a narrative review. Int J Bipolar Disord. 2015 Dec;3(1):32. doi: 10.1186/s40345-015-0032-2. Epub 2015 Jul 18
Lewitzka U, Bauer M. What Role Does (Should) Lithium Play in Suicide Treatment/Prevention? Psychiatric Times, 2014; 10-15
Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B. Anti-suicidal effect of lithium: current state of research and its clinical implications for the long-term treatment of affective disorders. Nervenarzt. 2013 Mar;84(3):294-306. German
McGirr A, Renaud J, Seguin M, Alda M, Benkelfat C, Lesage A, Turecki G. An examination of DSM-IV depressive symptoms and risk for suicide completion in major depressive disorder: a psychological autopsy study. J Affect Disord 2007;97:203-209
McGirr A, Seguin M, Renaud J, Benkelfat C, Alda M, Turecki G. Gender and risk factors for suicide: evidence for heterogeneity in predisposing mechanisms in a psychological autopsy study. J Clin Psychiatry 2006;67:1612-1617
Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology 2010;62:43-49
Müller-Oerlinghausen B, Ahrens B, Felber W. The suicide-preventive and mortality-reducing effect of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B (Eds.) Lithium in Neuropsychiatry. Informa healthcare 2006
Mueller-Oerlinghausen B, Felber W, Berghofer A, Lauterbach E, Ahrens B. The impact of lithium long-term medication on suicidal behavior and mortality of bipolar patients. Arch Suicide Res 2005;9:307-319
Müller-Oerlinghausen B, Roggenbach J, Franke L. Serotonergic platelet markers of suicidal behavior–do they really exist? J Affect Disord 2004;79:13-24
Müller-Oerlinghausen B. How should findings on antisuicidal effects of lithium be integrated into practical treatment decisions? Eur Arch Psychiatry Clin Neurosci 2003;253:126-131
Müller-Oerlinghausen B, Berghöfer A, Ahrens B. The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 2003;48:433-439
Müller-Oerlinghausen B, Berghöfer A. Antidepressants and suicidal risk. J Clin Psychiatr 1999;60 (suppl.2):94-99
Müller-Oerlinghausen B, Wolf T, Ahrens B, Glaenz T, Schou M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Vestergaard P, Wolf R. Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-Treated patients (IGSLi). Acta Psychiatr Scand 1996;94:344-347
Müller-Oerlinghausen B, Wolf T, Ahrens B, Schou M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Wolf R. Mortality during initial and during later lithium treatment: a collaborative study by the International Group for the Study of Lithium-treated Patients (IGSLi). Acta Psychiatr Scand 1994;90:295-297
Müller-Oerlinghausen B. Die IGSLI-Studie zur Mortalität Lithium-behandelter Patienten mit affektiven Psychosen. In: Müller-Oerlinghausen B, Berghöfer A (Hrsg.) Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Georg Thieme Verlag Stuttgart, 1994;S. 35-40
Müller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, Simhandl C, Thau K, Volk J, Wolf R, Wolf T. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 1992;86:218-222
Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patients group on and off lithium long-term medication. J Affect Disord 1992;25:261-269
Müller-Oerlinghausen B, Ahrens B, Volk J, Grof P, Grof E, Schou M, Vestergaard P, Lenz G, Simhandl C, Thau K, Wolf R. Letter: Reduced mortality of manic-depressive patients in long-term lithium treatment: an international collaborative study by IGSLi. Psychiat Res 1991;36:329-331
Nilsson A. Mortality in recurrent mood disorders during periods on and off lithium. A complete population study in 362 patients. Pharmacopsychiatry 1995;28:8-13
Rombold F, Lauterbach E, Felber W, Müller-Oerlinghausen B, Ahrens B, Bronisch T, Kilb B, Lewitzka U, Richter K, Broocks A, Heuser I, Hohagen F, Quante A. Adjunctive lithium treatment in the prevention of suicidal behavior in patients with depression and comorbid personality disorders. Int J Psychiatry Clin Pract 2014;18(4):300-3
Wolf T, Müller-Oerlinghausen B, Ahrens B, Grof P, Schou M, Felber W, Grof E, Lenz G, Nilsson A, Simhandl C, Thau K, Vestergaard P, Wolf R. How to interpret findings on mortality of long-term lithium treated manic-depressive patients?! Critique of different methodological approaches. J Affect Disord 1996;39:127-132
Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry 2015
Alda M, Shao L, Wang JF, Lopez de LC, Jaitovich-Groisman I, Lebel V, Sun X, Duffy A, Grof P, Rouleau GA, Turecki G, Young LT. Alterations in phosphorylated cAMP response element-binding protein (pCREB) signaling: an endophenotype of lithium-responsive bipolar disorder? Bipolar Disord 2013; 15: 824-831.
Alda M, Grof P, Rouleau GA, Turecki G, Young LT. Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):1038-1045
Alda M. Pharmacogenetic aspects of bipolar disorder. Pharmacogenomics 2003;4:35-40
Alda M. Genetic factors and response to prophylactic treatment in bipolar disorder. In: Lerer B (ed) Pharmacogenetics of Psychotropics Drugs. Cambridge University Press, Cambridge, 2002
Alda M, Keller D, Grof E, Turecki G, Cavazzoni P, Duffy A, Rouleau GA, Grof P, Young LT. Is lithium response related to gs_ levels in transformed lymphoblasts from subjects with bipolar disorder? J Aff Disord 2001;65:117-122
Alda M. Genetic factors and treatment of mood disorders. Bipolar Disord 2001;3:318-324
Alda M, Grof P. Genetics and lithium response in bipolar disorders. In: Soares JC, Gershon S (ed) Basic Mechanisms and Therapeutic Implications of Bipolar Disorder. Marcel Dekker, NY, 2000
Alda M, Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghöfer A, Müller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA. Association and linkage studies of CRH and PENK genes in bipolar disorder: a collaborative IGSLI study. Am J Medical Genetics 2000;96:178-181
Alda M, Grof P, Ravindran L, Cavazzoni P, Duffy A, Grof E, Zvolsky P, Wilson J. Anticipation in bipolar illness: Is age at onset a valid criterion? Am J Med Gen 2000;96:804-807
Alda M, Cavazzoni P, Grof P. Treatment response to prophylactic lithium and family history of psychiatric disorders (letter to the editor). Biol Psychiatry 1999;45:1078
Alda M. Pharmacogenetics of lithium response in bipolar disorder. J Psychiatr Neurosci 1999;24:154-158
Alda M, Grof P, Grof E. MN blood groups and bipolar disorder: evidence of genotypic association and Hardy-Weinberg disequilibrium. Biol Psychiatry 1998;44:361-363
Alda M. Bipolar disorder: from families to genes. Can J Psychiatry 1997;42:378-387
Alda M, Turecki G, Grof P, Ahrens B, Berghöfer A, Cavazzoni P, Duffy A, Dvorakova M, Grof E, Holzinger A, Libigerova E, Licht RW, Martin B, Müller-Oerlinghausen B, Nilsson A, Prochazka H, Rasmussen NA, Rouleau GA, Schou M, Schumann C, Thau K, Vestergaard P, Vojtechovsky M, Zvolsky P. Molecular genetic investigations of candidate loci in lithium responsive bipolar disorder – a study by IGSLI. Europ Neuropsychopharmacol 1997;7 (suppl.2):S177
Alda M, Grof E, Cavazzoni P, Duffy A, Martin R, Ravindran L, Grof P. Autosomal recessive inheritance in families of responders to lithium prophylaxis. J Aff Disord 1997;44:153-157
Alda M, Grof P, Grof E, Zvolsky P, Walsh M. Mode of inheritance in families of patients with lithium-responsive affective disorders. Acta Psychiatr Scand 1994;90:304-310
Alda M, Grof P, Cameron P. Lithium as a tool in genetic research. In: Birch N (ed) Lithium in Medicine and Biology. Marius Press, 1993
Alda M, Zvolsky P, Grof P, Walsh M. Prophylactic lithium response and genetics of primary affective disorders. In: Kuhne GE (ed) Aktuelle Apekte der Psychiatrie. Universitatsverlag Jena, 1991
Cavazzoni P, Grof P, Duffy A, Grof E, Muller-Oerlinghausen B, Berghöfer A, Ahrens B, Zvolsky P, Robertson C, Davis A, Hajek T, Alda M. Heterogeneity of the risk of suicidal behavior in bipolar-spectrum disorders. Bipolar Disord. 2007;9:377-385
Cavazzoni P, Alda M, Turecki G, Rouleau G, Grof E, Martin R, Duffy A, Grof P. Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Res 1996; 64:91-96
Cruceanu C, Alda M, Dion PA, Turecki G, Rouleau GA. No evidence for GADL1 variation as a bipolar disorder susceptibility factor in a Caucasian lithium-responsive cohort. Am J Psychiatry 2015; 172: 94-95
Cruceanu C, Ambalavanan A, Spiegelman D, Gauthier J, Lafreniere RG, Dion PA, Alda M, Turecki G, Rouleau GA. Family-based exome-sequencing approach identifies rare susceptibility variants for lithium-responsive bipolar disorder. Genome 2013; 56: 634-640
de Lara CL, Brezo J, Rouleau G, Lesage A, Dumont M, Alda M, Benkelfat C, Turecki G. Effect of tryptophan hydroxylase-2 gene variants on suicide risk in major depression. Biol Psychiatry 2007;62:72-80
Demidenko N, Grof P, Alda M, Deshauer D, Duffy A. MMPI as a measure of subthreshold and residual psychopathology among the offspring of lithium responsive and non-responsive bipolar parents. Bipolar Disord 2004;6:323-328
Deshauer D, Duffy A, Meaney M, Sharma S, Grof P. Salivary cortisol secretion in remitted bipolar patients and offspring of bipolar parents. Bipolar Disord 2006;8:345-349
Duffy A, Alda M, Trinneer A, Demidenko N, Grof P, Goodyer IM. Temperament, life events, and psychopathology among the offspring of bipolar parents. Eur Child Adolesc Psychiatry 2007;16:222-228
Duffy A, Kutcher S, Alda M, Grof P. Hypotheses genetiques et troubles de l’humeur a debut precoce. In: Mamdani F, Sequeira A, Alda M, Grof P, Rouleau G, Turecki G. No association between the PREP gene and lithium responsive bipolar disorder. BMC Psychiatry 2007;7:9
Duffy A, Alda M, Kutcher S, Robertson C, Grof E, Grof P. A prospective study of the offspring of bipolar parents responsive and non-responsive to lithium treatment. J Clin Psychiatry 2002;63:1171-1178
Duffy A. Editorial. Adolescents with psychiatric disorders: When to treat? And with what? Can J Psychiatry 2001;46:795-796
Duffy A, Grof P. Psychiatric diagnoses in the context of genetic studies of bipolar disorder. J Bip Disord 2001;3:270-275
Duffy A, Grof P, Kutcher S, Robertson C, Alda M. Measures of attention and hyperactivity symptoms in a high-risk sample of children of bipolar parents. J Aff Disord 2001;67:159-165
Duffy A, Grof P, Robertson C, Alda M. The implications of genetic studies of major mood disorders for clinical practice. J Clin Psychiatry 2000;61(9):630-637
Duffy A. Towards effective early intervention and prevention strategies for major affective disorders: A review of antecedents and risk factors. Can J Psychiatry 2000;45:340-348
Duffy A, Turecki G, Grof P, Cavazzoni P, Grof E, Joober R, Ahrens B, Berghöfer A, Müller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Nilsson A, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Robertson C, Rouleau GA, Alda M. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium responsive bipolar disorder. J Psychiatry Neurosci 2000;25:353-358
Duffy A, Alda M, Kutcher S, Fusee C, Grof P. Psychiatric symptoms and syndromes among the adolescent children of bipolar patients divided on the basis of response to lithium prophylaxis. Am J Psychiatry 1998;155:431-433
Duffy A, Grof P, Grof E, Zvolsk_ P, Alda M. Evidence supporting the independent inheritance of primary affective disorders and primary alcoholism in the families of bipolar patients. J Aff Disord 1998; 50:91-96
Ftouhi-Paquin N, Alda M, Grof P, Chretien N, Rouleau G, Turecki G. Identification of three polymorphisms in the translated region of PLC-gamma1 and their investigation in lithium responsive bipolar disorder. Am J Med Genet 2001;105:301-305
Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O’Donovan C, Alda M. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002;63:942-947
Grof P, Alda M, Grof E, Zvolsky P, Walsh M. Lithium response and genetics of affective disorders. J Affect Disord 1994;32:85-95
Hauser J, Leszczy_ska A, Samochowiec J, Ostapowicz A, Czerski P, Jaracz J, Suwalska A, Horodnicki J, Rybakowski J. The association study of a functional polymorphism of the monoamine A gene promoter in patients with affective disorders. Arch Psychiatry Psychother 2002;4:9-15
Hunsberger JG, Chibane FL, Elkahloun AG, Henderson R, Singh R, Lawson J, Cruceanu C, Nagarajan V, Turecki G, Squassina A, Medeiros CD, Del ZM, Rouleau GA, Alda M, Chuang DM. Novel integrative genomic tool for interrogating lithium response in bipolar disorder. Transl Psychiatry 2015; 5: e504
Huzayyin AA, Andreazza AC, Turecki G, Cruceanu C, Rouleau GA, Alda M, Young LT. Decreased global methylation in patients with bipolar disorder who respond to lithium. Int J Neuropsychopharmacol 2014; 17: 561-569
Klaning U, Laursen TM, Licht RW, Kyvik KO, Skytthe A, Mortensen PB. Is the risk of bipolar disorder in twins equal to the risk in singletons? A nationwide register-based study. J Affect Disord 2004;81:141-145
MacQueen GM, Hajek T, Alda M. The phenotypes of bipolar disorder: relevance for genetic investigations. Mol Psychiatry 2005;10:811-826
MacQueen GM, Grof P, Alda M, Marriott M, Young LT, Duffy A. A pilot study of visual backward masking performance among affected versus unaffected offspring of parents with bipolar disorder. Bipolar Disord 2004;6:374-378
Mamdani F, Groisman IJ, Alda M, Turecki G. Pharmacogenetics and bipolar disorder. Pharmacogenomics J 2004;4:161-170
Mamdani F, Jaitovich Groisman I, Alda M, Turecki G. Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications. Curr Psychiatry Rep 2003;5:484-492
Manchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L, Banzato CE, Baune BT, Bellivier F, Bengesser S, Biernacka JM, Brichant-Petitjean C, Bui E, Calkin CV, Cheng AT, Chillotti C, Cichon S, Clark S, Czerski PM, Dantas C, Zompo MD, Depaulo JR, tera-Wadleigh SD, Etain B, Falkai P, Frisen L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hou L, Jamain S, Kahn JP, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwicki S, Kuo PH, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband SG, Lopez Jaramillo CA, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell PB, Mondimore F, Monteleone P, Nallet A, Neuner M, Novak T, O’Donovan C, Osby U, Ozaki N, Perlis RH, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert OK, Schweizer B, Seemuller F, Grigoroiu-Serbanescu M, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe SK, Tortorella A, Turecki G, Wray NR, Wright A, Zandi PP, Zilles D, Bauer M, Rietschel M, McMahon FJ, Schulze TG, Alda M. Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS One 2013; 8: e65636.
Manchia M, Hajek T, O’Donovan C, Deiana V, Chillotti C, Ruzickova M, Del ZM, Alda M. Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disord 2013; 15: 496-506
Manchia M, Congiu D, Squassina A, Lampus S, Ardau R, Chillotti C, Severino G, Del Zompo M. No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Research 2009;169:164-166
Manchia M, Squassina A, Congiu D, Chillotti C, Ardau R, Severino G, Del Zompo M. Interacting genes in lithium prophylaxis: Preliminary results of an exploratory analysis on the role of DGKH and NR1D! gene polymorphisms in 199 Sardinian bipolar patients. Neuroscience Letters 2009;467:67-71
Mansour HA, Alda M, Nimgaonkar VL. Pharmacogenetics of bipolar disorder. Curr Psychiatry Rep 2002;4:17-123.
Mouren-Simeoni MC, Klein RG (ed) Les depressions chez l’enfant et l’adolescent. Faits et questions. Expansion Scientifique Publications, Paris, 1997
Muhleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, Mattheisen M, Forstner AJ, Schumacher J, Breuer R, Meier S, Herms S, Hoffmann P, Lacour A, Witt SH, Reif A, Muller-Myhsok B, Lucae S, Maier W, Schwarz M, Vedder H, Kammerer-Ciernioch J, Pfennig A, Bauer M, Hautzinger M, Moebus S, Priebe L, Czerski PM, Hauser J, Lissowska J, Szeszenia-Dabrowska N, Brennan P, McKay JD, Wright A, Mitchell PB, Fullerton JM, Schofield PR, Montgomery GW, Medland SE, Gordon SD, Martin NG, Krasnow V, Chuchalin A, Babadjanova G, Pantelejeva G, Abramova LI, Tiganov AS, Polonikov A, Khusnutdinova E, Alda M, Grof P, Rouleau GA, Turecki G, Laprise C, Rivas F, Mayoral F, Kogevinas M, Grigoroiu-Serbanescu M, Propping P, Becker T, Rietschel M, Nothen MM, Cichon S. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun 2014; 5: 3339.
Niola P, Gross JA, Lopez JP, Chillotti C, Deiana V, Manchia M, Georgitsi M, Patrinos GP, Alda M, Turecki G, Del ZM, Squassina A. Lithium-induced differential expression of SAT1 in suicide completers and controls is not correlated with polymorphisms in the promoter region of the gene. Psychiatry Res 2014; 220: 1167-1168.
Passmore MJ, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, Teehan A, Alda M. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003;5:110-114
Ruzickova M, Turecki G, Alda M. Pharmacogenetics and mood stabilization in bipolar disorder. Am J Med Genet C Semin Med Genet 2003;123:18-25
Schulze TG, Alda M, Adli M, Akula N, Ardau R, Chillotti C, Cichon S, Czerski P, DelZompo M, Detera-Wadleigh SD, Grof P, Gruber O, Hashimoto R, Hauser J, Hoban R, Iwata N, Kassem L, Kato T, Kittel-Schneider S, Kliwicki S, Kelsoe JR, Kusumi I, Laje G, Leckband SG, Manchia M, MaQueen G. Masui T, Ozaki N, Perlis RH, Pfennig A, Piccardi P, Richardson S, Rouleau G, Reif A, Rybakowski JK, Sasse J, Schumacher J, Severino G, Smoller JW, Squassina A, Turecki G, Young KT, Yoshikawa T, Bauer M, McMahon FJ. The International Consortium on Lithium Genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 2010;62:72-78
Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI Jr, Craddock N, DePaulo JR, Baron M, Gershon ES, Ekholm J, Cichon S, Turecki G, Claes S, Kelsoe JR, Schofield PR, Badenhop RF, Morissette J, Coon H, Blackwood D, McInnes LA, Foroud T, Edenberg HJ, Reich T, Rice JP, Goate A, McInnis MG, McMahon FJ, Badner JA, Goldin LR, Bennett P, Willour VL, Zandi PP, Liu J, Gilliam C, Juo SH, Berrettini WH, Yoshikawa T, Peltonen L, Lonnqvist J, Nothen MM, Schumacher J, Windemuth C, Rietschel M, Propping P, Maier W, Alda M, Grof P, Rouleau GA, Del-Favero J, Van Broeckhoven C, Mendlewicz J, Adolfsson R, Spence MA, Luebbert H, Adams LJ, Donald JA, Mitchell PB, Barden N, Shink E, Byerley W, Muir W, Visscher PM, Macgregor S, Gurling H, Kalsi G, McQuillin A, Escamilla MA, Reus VI, Leon P, Freimer NB, Ewald H, Kruse TA, Mors O, Radhakrishna U, Blouin JL, Antonarakis SE, Akarsu N. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet 2003;73:49-62
Severino G, Squassina A, Costa M, Pisanu C, Calza S, Alda M, Del ZM, Manchia M. Pharmacogenomics of bipolar disorder. Pharmacogenomics 2013; 14: 655-674
Squassina A, Manchia M, Chillotti C, Deiana V, Congiu D, Paribello F, Roncada P, Soggiu A, Piras C, Urbani A, Robertson GS, Keddy P, Turecki G, Rouleau GA, Alda M, Del ZM. Differential effect of lithium on spermidine/spermine N1-acetyltransferase expression in suicidal behaviour. Int J Neuropsychopharmacol 2013; 16: 2209-2218
Squassina D, Congiu D, Manconi F, Manchia M, Chillotti C, Lampus S, Severino G, Del Zompo M. The PDLIM5 gene and lithium prophylaxis: An association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacological Research 2008;57:369-373
Sun X, Young LT, Wang JF, Grof P, Turecki G, Rouleau GA, Alda M. Identification of lithium-regulated genes in cultured lymphoblasts of lithium responsive subjects with bipolar disorder. Neuropsychopharmacol 2004;29:799-804
Turecki G, Grof P, Grof E, D’Souza V, Lebuis L, Marineau C, Cavazzoni P, Duffy A, Robertson C, Betard C, Zvolsky P, Brewer C, Hudson T, Rouleau GA, Alda M. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry 2001;6:570-578
Turecki G, Alda M, Grof P, Joober R, Lafrenière R, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghöfer A, Müller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA. Polyglutamine coding genes in bipolar disorder. Lack of association with selected candidate loci. J Affect Disord 2000;58:63-68
Turecki G, Alda M, Grof P, Joober R, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghöfer A, Müller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA. Polyglutamine tracts: no evidence of a major role in bipolar disorder. Molecular Psychiatry 1999;4:220-221
Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghöfer A, Müller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA, Alda M. MAOA: Association and linkage studies with lithium responsive bipolar disorder. Psychiatric Genetics 1999;9:13-16
Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Martin R, Joober R, Rouleau GA, Alda M. Lithium responsive bipolar disorder, parental origin and chromosome 18: a linkage study. Am J Med Gen 1999;88:411-415
Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghöfer A, Müller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann C, Thau K, Rouleau GA, Alda M. Evidence for a role of phospholipase C-g1 in the pathogenesis of bipolar disorder. Molecular Psychiatry 1998;3:534-538 Turecki G, Alda M, Grof P, Grof E, Martin R, Cavazzoni P, Duffy A, Maciel P, Rouleau G. No association between chromosome 18 markers and lithium responsive affective disorders. Psychiatry Research 1996;63:17-23
Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M. Response to Lithium Augmentation in Depression is Associated with the Glycogen Synthase Kinase 3-Beta -50T/C Single Nucleotide Polymorphism. Biol Psychiatry. 2007
Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R. Lithium´s emerging role in the treatment of refractory major depressive episodes: Augmenation of antidepressants. Neuropsychobiology 2010;62:36-42
Bauer M, Adli M, Baethge C, Berghöfer A, Sasse J, Heinz A, Bschor T. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003;48:440-448
Bauer M, Forsthoff A, Baethge C, Adli M, Berghöfer A, Döpfmer S, Bschor T. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 2003;253:132-139
Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle S, Müller-Oerlinghausen B. Lithium discontinuation: uncovering latent bipolar disorder? Dr. Bauer and colleagues reply. Am J Psychiatry 2001;158:1338-1339
Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle S, Müller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatr 2000;157:1429-1435
Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression – A meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999;19:427-434
Bschor T. Therapy-resistant depression. Expert Rev Neurother 2010;10:77-86
Bschor T, Lewitzka U, Pfennig A, Bauer M. [Twenty-five years of lithium augmentation.] Nervenarzt. 2007 Apr 26
Bschor T, Lewitzka U, Pfennig A, Bauer M. Twenty-five years of lithium augmentation. Nervenarzt 2007;78:1237-1247
Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des. 2006;12:2985-2992
Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, Modell S, Kunzel H, Müller-Oerlinghausen B, Bauer M. Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. J Psychiatr Res 2003;37:135-143
Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, Müller-Oerlinghausen B, Bauer M. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress Anxiety 2003;17:43-48
Bschor T, Baethge C, Adli M, Lewitzka U, Eichmann U, Bauer M. Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression. J Psychiatry Neurosci 2003;28:210-216
Bschor T, Lewitzka U, Sasse J, Adli M, Koberle U, Bauer M. Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry 2003;36 Suppl 3:S230-S234
Bschor T, Adli M, Baethge C, Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 2002;27:470-478
Bschor T, Berghöfer A, Ströhle A, Kunz D, Adli M, Müller-Oerlinghausen B, Bauer M. How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar major depression. J Clin Psychopharmacol 2002;22:427-430
Bschor T, Canata B, Müller-Oerlinghausen B, Bauer M. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 2001;64:261-265
Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935-940
Kok RM, Vink D, Heeren TJ, Nolen WA. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. J Clin Psychiatry. 2007 Aug;68(8):1177-85
Ricken R, Bopp S, Schlattmann P, Himmerich H, Bschor T, Richter C, Stamm TJ, Bauer F, Heinz A, Hellweg R, Lang UE, Adli M: Leptin serum concentrations are associated with weight gain during lithium augmentation. Psychoneuroendocrinology 2016;71:31-35
Ricken R, Adli M, Lange C, Krusche E, Stamm TJ, Gaus S, Koehler S, Nase S, Bschor T, Richter C, Steinacher B, Heinz A, Rapp MA, Borgwardt S, Hellweg R, Lang UE: Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants. J Clin Psychopharmacol 2013:33:806-9
Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in the treatment resistant depression. Neuropsychobiology 1999;3:134-139
Bowden C, Göğüş A, Grunze H, Häggström L, Rybakowski J, Vieta E. A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. Int Clin Psychopharmacol 2008;23:254-262
Gouliaev G, Licht RW, Vestergaard P, Merinder L, Lund H, Bjerre L. Treatment of manic episodes: zuclopenthixol and clonazepam versus lithium and clonazepam. Acta Psychiatr Scand 1996;93:119-124
Licht RW. Limits of the applicability and generalizability of drug trials in mania. Bipolar Disord 2002;4(Suppl 1):66-68
Licht RW. Limitations in randomised controlled trials evaluating drug effects in mania. Eur Arch Psychiatry Clin Neurosci 2001;251(Suppl 2):II66-71 Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998;97:387-397 Licht RW, Gouliaev G, Vestergaard P, Frydenberg M. Generalisability of results from randomised drug trials. A trial on antimanic treatment. Br J Psychiatry 1997;170:264-267
Amsterdam JD, Rybakowski J, Gottlieb J, Frazer A. Kinetics of erythrocyte lithium-sodium countertransport in patients with affective illness before and during lithium therapy. J Affect Disord 1988;14:75-81
Bschor T, Bauer M. Is successful lithium augmentation limited to serotonergic antidepressants? [letter] J Clin Psychopharmacol 2004;24:240-241
Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Szczepankiewicz A, Hauser J. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008;9:1595-1603
Felber W, König L. [Struma (goitre) caused by lithium and its psychiatric relevance] Psychiat Prax 1988;15:57-61 (german)
Fiebich BL, Akundi RS, Biber K, Hamke M, Schmidt C, Butcher RD, van Calker D, Willmroth F. IL-6 expression induced by adenosine A2b receptor stimulation in U373 MG cells depends on p38 mitogen activated kinase and protein kinase C. Neurochem Int 2005;46:501-512
Förstner U, Bohus M, Gebicke-Härter PJ, Baumer B, Berger M, van Calker D. Decreased agonist-stimulated Ca2+-response in neutrophils from patients under chronic lithium therapy. Eur Arch Psychiatry Neurol Sci 1994;243:240-243
Frazer A, Mendels J, Brunswick D, London J, Pring M, Ramsey TA, Rybakowski J. Erythrocyte concentrations of the lithium ion: clinical correlates and mechanisms of action. Am J Psychiatry 1978;135:1065-1069
Greil W, Steber R, van Calker D. The agonist-stimulated accumulation of inositol phosphates is attenuated in neutrophils from male patients under chronic lithium therapy. Biol Psychiatry 1991;30:443-451
Lehmann W, Kanarkowski R, Matkowski K, Rybakowski J. Studies of lithium pharmacokinetics in patients with affective illness. Pol J Pharmacol Pharm 1988;40:47-54
Licht RW, Larsen JO, Smith D, Braendgaard H. Chronic lithium treatment with or without haloperidol fails to affect the morphology of the rat cerebellum. Eur Neuropsychopharmacol. 2003;13:173-176
Licht RW, Larsen JO, Smith D, Braendgaard H. Effect of chronic lithium treatment with or without haloperidol on number and sizes of neurons in rat neocortex. Psychopharmacology 1994;115:371-374
Lubrich B, van Calker D. Inhibition of the high affinity myo-inositol uptake: A common mechanism of action of antibipolar drugs? Neuropsychopharmacology 1999;21:519-529
Lubrich B, Patishi Y, Kofman O, Berger M, Belmaker RH, van Calker D. Lithium-induced inositol depletion in rat brain after chronic treatment is restricted to the hypothalamus. Mol Psychiatry 1997;2:407-412
MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT, Nahmias C, Young LT. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci 2003;100:1387-1392
Rybakowski JK, Dmitrzak-Weglarz M, Suwalska A, Leszczynska-Rodziewicz A, Hauser J. Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder. Pharmacopsychiatry 2009;42:20-22
Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet 2007;144B:820-823
Rybakowski JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005;57:124-127
Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A, Czerski PM, Hauser J. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005;38:166-170
Rybakowski J. Mechanisms of the psychotropic action of lithium and carbamazepine. Pharmacol Toxicol 1992;71(Suppl 1):30-41
Rybakowski JK, Lehmann W. Abnormalities of lithium transport across the erythrocyte membrane in depression and schizophrenia. Biol Psychiatry 1991;29:340-346
Rybakowski J, Lehmann W, Matkowski K. Dissimilar effects of lithium and carbamazepine on erythrocyte lithium transport in vivo: clinical implications. Pol J Pharmacol Pharm 1990;42:113-120
Rybakowski JK, Amsterdam JD, Dyson WL, Frazer A, Winokur A, Kurtz J. Factors contributing to erythrocyte lithium-sodium countertransport activity in lithium-treated bipolar patients. Pharmacopsychiatry 1989;22:16-20
Rybakowski J, Potok E, Strzyzewski W, Chlopocka-Wozniak M. The effects of lithium treatment on cation transport processes in erythrocytes of patients with affective illnesses. Pol J Pharmacol Pharm 1983;35:209-215
Rybakowski J, Potok E, Strzyzewski W. The activity of the lithium-sodium countertransport system in erythrocytes in depression and mania. J Affect Disord 1981;3:59-64
Rybakowski J, Frazer A, Mendels J, Ramsey TA. Erythrocyte accumulation of the lithium ion in control subjects and patients with primary affective disorder. Commun Psychopharmacol 1978;2:99-104
Rybakowski J, Frazer A, Mendels J. Lithium efflux from erythrocytes incubated in vitro during lithium carbonate administration. Commun Psychopharmacol 1978;2:105-112
Rybakowski J, Frazer A, Mendels J, Ramsey TA. Prediction of the lithium ratio in man by means of an in vitro test. Clin Pharmacol Ther 1977;22:465-469
Rybakowski J, Chlopocka M, Kapelski Z, Hernacka B, Szajnerman Z, Kasprzak K. Red blood cell lithium index in patients with affective disorders in the course of lithium prophylaxis. Int Pharmacopsychiatry 1974;9:166-171
Szczepankiewicz A, Skibińska M, Suwalska A, Hauser J, Rybakowski JK. No association of three GRIN2B polymorphisms with lithium response in bipolar patients. Pharmacol Rep 2009;61:448-452
Szczepankiewicz A, Skibinska M, Suwalska A, Hauser J, Rybakowski JK. The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients. Hum Psychopharmacol 2009;24:287-291
Szczepankiewicz A, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Dmitrzak-Weglarz M, Czerski PM, Hauser J. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry 2006;7:158-161
Spleiss O, van Calker D, Schärer L, Adamovic K, Berger M, Gebicke-Härter PJ. Abnormal G-protein ai2- and a0 -subunit mRNA expression in bipolar affective disorder. Mol Psychiatry 1998;3:512-520
van Calker D. Molecular mechanisms of action of mood stabilizers in bipolar disorder. In: Kaschka WP (Ed.) Perspectives in Affective Disorders. Adv Biol Psychiatry Vol. 21, Karger, Basel 2002, pp. 112-136
van Calker D, Belmaker RH. News and Views – The high affinity inositol transport system – implications for the pathophysiology and treatment of bipolar disorders. Bipolar Disord 2000;2:102-107
van Calker D, Förstner U, Bohus M, Gebicke-Härter PJ, Wark HJ, Berger M. Increased sensitivity to agonist-stimulation of the Ca2+-response in neutrophils of manic-depressive patients: effect of lithium therapy. Neuropsychobiology 1993;27:180-183
Willmroth F, Spleiss O, Wiesmann K, Moser D, Atmanspacher R, van Calker D. Expression of G-proteins and regulators of G-protein signalling in neutrophils of patients with bipolar disorder: effects of mood stabilizers. Bipolar Disord 2002;4(Suppl 1):75-76
Wysocki H, Rybakowski J, Wierusz-Wysocka B, Szajnerman Z, Michta G, Kapelski Z. Influence of lithium on neutrophil granulocyte distribution and turnover. Folia Haematol Int Mag Klin Morphol Blutforsch 1981;108:533-538
Young LT, Bezchlibnyk YB, Chen B, Wang JF, MacQueen GM. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biol Psychiatry 2004;55:570-577
Zaremba D, Rybakowski J. Erythrocyte lithium transport during lithium treatment in patients with affective disorders. Pharmacopsychiatry 1986;19:63-67
Adli M, Bschor T, Bauer M, Lucka C, Lewitzka U, Ising M, Uhr M, Müller-Oerlinghausen B, Baethge C. Long-term outcome after lithium augmentation in unipolar depression: focus on HPA system activity. Neuropsychobiology 2009;60:23-30
Bauer M, Alda M, Priller J, Young LT; International Group For The Study Of Lithium Treated Patients (IGSLI). Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry. 2003;36 Suppl 3:S250-254
Bschor T, Ritter D, Winkelmann P, Erbe S, Uhr M, Ising M, Lewitzka U. Lithium monotherapy increases ACTH and cortisol response in the Dex/CRH test in unipolar depressed subjects. A study with 30 treatment-naive patients. PLoS ONE 2011;6(11): e27613
Cruceanu C, Alda M, Grof P, Rouleau GA, Turecki G. Synapsin II is involved in the molecular pathway of lithium treatment in bipolar disorder. PLoS One 2012; 7: e32680
Hajek T, Bauer M, Simhandl C, Rybakowski J, O’Donovan C, Pfennig A, Konig B, Suwalska A, Yucel K, Uher R, Young LT, MacQueen G, Alda M. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med 2014; 44: 507-517
Hajek T, Cullis J, Novak T, Kopecek M, Blagdon R, Propper L, Stopkova P, Duffy A, Hoschl C, Uher R, Paus T, Young LT, Alda M. Brain structural signature of familial predisposition for bipolar disorder: replicable evidence for involvement of the right inferior frontal gyrus. Biol Psychiatry 2013; 73: 144-152
Hajek T, Cullis J, Novak T, Kopecek M, Hoschl C, Blagdon R, O’Donovan C, Bauer M, Young LT, MacQueen G, Alda M. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord 2012; 14: 261-270
Hajek T, Bauer M, Pfennig A, Cullis J, Ploch J, O’Donovan C, Bohner G, Klingebiel R, Young LT, Macqueen GM, Alda M. Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. J Psychiatry Neurosci 2012; 37: 185-192.
Hajek T, Kopecek M, Hoschl C, Alda M. Smaller hippocampal volumes in patients with bipolar disorder are masked by exposure to lithium: a meta-analysis. J Psychiatry Neurosci 2012; 37: 333-343
Hajek T, Kopecek M, Preiss M, Alda M, Hoschl C. Prospective study of hippocampal volume and function in human subjects treated with corticosteroids. Eur Psychiatry 2006;21:123-128
Pfennig A, Alda M, Young T, MacQueen G, Rybakowski J, Suwalska A, Simhandl C, Konig B, Hajek T, O’Donovan C, Wittekind D, von QS, Ploch J, Sauer C, Bauer M. Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: no simple answers in complex disease-treatment interplay. Int J Bipolar Disord 2014; 2: 1.
Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 2010;13:617-622
Rybakowski JK, Permoda-Osip A, Borkowska A. Response to prophylactic lithium in bipolar disorder may be associated with a preservation of executive cognitive functions. Eur Neuropsychopharmacol 2009;19:791-795
Schmitt A, Bauer M, Heinsen H, Feiden W; The Consortium of Brainnet Europe II, Falkai P, Alafuzoff I, Arzberger T, Al-Sarraj S, Bell JE, Bogdanovic N, Bruck W, Budka H, Ferrer I, Giaccone G, Kovacs GG, Meyronet D, Palkovits M, Parchi P, Patsouris E, Ravid R, Reynolds R, Riederer P, Roggendorf W, Schwalber A, Seilhean D, Kretzschmar H. How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. J Neural Transm 2007;114:527-537
Suwalska A, Sobieska M, Rybakowski JK. Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 2010;62:229-234
Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001;158:1617-1622
Baethge C, Reischies FM, Berghöfer A, Baur H, Schlattmann P, Whybrow PC, Bauer M. Effects of supraphysiological doses of thyroxine on cognitive function in healthy individuals. Psychiatry Res 2002; 110 (2):117-123
Bauer M, Fairbanks L, Berghoefer A, Hierholzer J, Bschor T, Baethge C, Rasgon N, Sasse J, Whybrow PC. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. J Affect Disord 2004;83:183-190
Bauer M, London ED, Silverman DH, Rasgon N, Kirchheiner J, Whybrow PC. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry. 2003;36 Suppl 3:S215-S221
Bauer M, Baur H, Berghöfer A, Ströhle A, Hellweg R, Müller-Oerlinghausen B, Baumgartner A. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. J Affect Disord 2002;68:285-294
Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, Adli M, Baethge C, Müller-Oerlinghausen B. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002;27:620-628
Bauer M, Heinz A, Whybrow PC Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry 2002;7:140-156
Bauer M, Priebe S, Berghöfer A, Bschor T, Kiesslinger K, Whybrow PC. Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. J Affect Disord 2001;64:35-42
Bauer M, Hellweg R, Gräf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacol 1998;18:444-455
Gitlin M, Altshuler LL, Frye MA, Suri R, Huynh EL, Fairbanks L, Bauer M, Korenman S. Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors. J Psychiatry Neurosci 2004;29:383-386
Gyulai L, Bauer M, Bauer MS, Garcia-Espana F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biol Psychiatry 2003;53:899-905
Gyulai L, Bauer M, Garcia-Espana F, Hierholzer J, Baumgartner A, Berghöfer A, Whybrow PC. Bone mineral density in pre- and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001;66:185-191
Adli M, Bauer M, Rush AJ. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry. 2006;59:1029-1038
Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005
Alda M. The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol 2004 May;14 Suppl 2:S94-S99
Baethge C, Tondo L, Lepri B, Baldessarini RJ: Coffee and cigarette use: association with suicidal acts in 352 Sardinian bipolar disorder patients. Bipolar Disord. 2009; 11:494–503
Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry 2005;162:1008-1010
Baethge C. The long-term treatment of Schizoaffective Disorder: Review and Recommendations. Pharmacopsychiatry 2003;36:45-56
Baldessarini RJ, Tondo L, Baethge CJ, Lepri B, Bratti IM: Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disord. 2007; 9:386–393
Bauer M, Blumentritt H, Finke R, Schlattmann P, Adli M, Baethge C, Bschor T, Muller-Oerlinghausen B, Berghöfer A. Using ultrasonography to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders. J Affect Disord 2007
Bauer R, Conell J, Glenn T, Alda M, Ardau R, Baune BT, Berk M, Bersudsky Y, Bilderbeck A, Bocchetta A, Bossini L, Castro AMP, Cheung EY, Chillotti C, Choppin S, Del Zompo M, Dias R, Dodd S, Duffy A, Etain B, Fagiolini A, Hernandez MF, Garnham J, Geddes J, Gildebro J, Gonzalez-Pinto A, Goodwin GM, Grof P, Harima H, Hassel S, Henry C, Hidalgo-Mazzei D, Kapur V, Kunigiri G, Lafer B, Larsen ER, Lewitzka U, Licht RW, Lund AH, Misiak B, Monteith S, Munoz R, Nakanotani T, Nielsen RE, O’Donovan C, Okamura Y, Osher Y, Piotrowski P, Reif A, Ritter P, Rybakowski JK, Sagduyu K, Sawchuk B, Schwartz E, Scippa ÂM, Slaney C, Sulaiman AH, Suominen K, Suwalska A, Tam P, Tatebayashi Y, Tondo L, Vieta E, Vinberg M, Viswanath B, Volkert J, Zetin M, Whybrow PC, Bauer M: Internet use by patients with bipolar disorder: Results from an international multisite survey. Psychiatry Res. 2016; 242:388–94
Bauer M. Updated WFSBP Guidelines for the Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8:66.
Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Moller HJ; WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8(2):67-104
Bauer M, Zaninelli R, Müller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: A double-blind study. J Clin Psychopharmamacol 1999;19:164-171
Bauer M, Linden M, Schaaf B, Weber HJ. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. J Clin Psychopharmacol 1996;6:130-134
Bauer M, Ahrens B. Bipolar disorder: A practical guideline for drug treatment. CNS Drugs 1996;6:35-52
Biber K, Lubrich B, Fiebich BL, Boddeke HW, van Calker D. Interleukin-6 enhances expression of adenosine A(1) receptor mRNA and signaling in cultured rat cortical astrocytes and brain slices. Neuropsychopharmacology. 2001 Jan;24(1):86-96.
Biber, K., Klotz K-N, Berger, M., Gebicke-Härter, P., van Calker, D. Adenosine A1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J. Neurosci. 1997; 17, 4956-4964
Biber K, Walden J, Gebicke-Härter P, Berger M, van Calker D. Carbamazepine inhibits the potentiation by adenosine analogues of agonist induced inositolphosphate formation in hippocampal astrocyte cultures. Biol Psychiatry. 1996 Oct 1;40(7):563-7
Bschor T, Müller-Oerlinghausen B, Stoppe G, Hiemke C. New facts of long-term prophylaxis for bipolar affective disorder. Nervenarzt 2014;85:1166-1170
Bschor T, Bauer M, Adli M. Chronic and treatment resistant depression – diagnosis and stepwise therapy. Dtsch Arztebl Int 2014;111:766-776
Bschor T. Lithium in the Treatment of Major Depressive Disorder. Drugs 2014; 74:855-862
Bschor T, Bauer M. Nebenwirkungs- und Risikoprofil von Lithium. Kritische Bewertung einer systematischen Übersicht und Metaanalyse. [Side effects and risk profile of lithium: critical assessment of a systematic review and meta-analysis]. Nervenarzt 2013; 84:860-863
Bschor T. Therapy-resistant depression. Expert Rev Neurother 2010;10:77-86
Bschor T, Adli M. Treatment of depressive disorders. Dtsch Arztebl Int 2008;105:782-792
Calkin C, Alda M. Beyond the guidelines for bipolar disorder: practical issues in long-term treatment with lithium. Can J Psychiatry 2012; 57: 437-445
Conell J, Bauer R, Glenn T, Alda M, Ardau R, Baune BT, Berk M, Bersudsky Y, Bilderbeck A, Bocchetta A, Bossini L, Paredes Castro AM, Cheung EYW, Chillotti C, Choppin S, Del Zompo M, Dias R, Dodd S, Duffy A, Etain B, Fagiolini A, Garnham J, Geddes J, Gildebro J, Gonzalez-Pinto A, Goodwin GM, Grof P, Harima H, Hassel S, Henry C, Hidalgo-Mazzei D, Kapur V, Kunigiri G, Lafer B, Lam C, Larsen ER, Lewitzka U, Licht R, Lund AH, Misiak B, Piotrowski P, Monteith S, Munoz R, Nakanotani T, Nielsen RE, O’Donovan C, Okamura Y, Osher Y, Reif A, Ritter P, Rybakowski JK, Sagduyu K, Sawchuk B, Schwartz E, Scippa ÂM, Slaney C, Sulaiman AH, Suominen K, Suwalska A, Tam P, Tatebayashi Y, Tondo L, Vieta E, Vinberg M, Viswanath B, Volkert J, Zetin M, Zorrilla I, Whybrow PC, Bauer M: Online information seeking by patients with bipolar disorder: results from an international multisite survey. Int. J. bipolar Disord. 2016; 4:17
Conell J, Lewitzka U, Ritter P, Severus E, Pihatsch M, Pfennig A, Berghöfer A, Bauer M. Is there an increased risk for renal tumors during long-term treatment with lithium? Nervenarzt. 2015 Sep;86(9):1157-61. doi: 10.1007/s00115-015-4413-7
Cruceanu C, Alda M, Rouleau G, Turecki G. Response to treatment in bipolar disorder. Curr Opin Psychiatry 2011; 24: 24-28
Faedda GL, Marangoni C, Serra G, Salvatore P, Sani G, Vázquez GH, Tondo L, Girardi P, Baldessarini RJ, Koukopoulos A: Precursors of bipolar disorders: a systematic literature review of prospective studies. J. Clin. Psychiatry 2015; 76:614–24
Felber W (ed). Reprint C. Lange: Periodische Depressionszustände und ihre Pathogenesis auf dem Boden der harnsauren Diathese. Übersetzg. aus dem Dänischen von A. Kurella., Hamburg, Leipzig: L Voß, 1896. Mit e. Vorwort von M. Schou. Regensburg: S Roderer, 1996
Felber W, König L. [Practical aspects of lithium therapy] Z ärztl Fortbild 1977;71:408-410 (german)
Felber W. [Lithium prophylaxis of depression 100 years ago – an ingenious misconception] Fortschr Neurol Psychiat 1987; 55:141-144 (german)
Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Möller HJ; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 2003;4:5-13
Hauser M, Pfennig A, Ozgurdal S, Heinz A, Bauer M, Juckel G. Early recognition of bipolar disorder. Eur Psychiatry. 2007;22:92-98
Hajek T, Alda M, Grof P. Discontinuation of lithium because of side effects. J Psychiatry Neurosci 2011; 36: E39-E40
Hajek T, Carrey N, Alda M. Neuroanatomical abnormalities as risk factors for bipolar disorder. Bipolar Disord 2005 ;7:393-403
Haußmann R, Bonin v S, Bauer M, Lewitzka U. Non-fatal lithium intoxication with 5.5mmol/l serum level. Pharmacopsychiatry. 2015 May;48(3):121-2
Haussmann R, Bauer M, von Bonin S, Grof P, Lewitzka U. Treatment of lithium intoxication: facing the need for evidence. Int J Bipolar Disord. 2015 Dec;3(1):23. doi: 10.1186/s40345-015-0040-2
Köhler S, Gaus S, Bschor T. The Challenge of Treatment in Bipolar Depression: Evidence from Clinical Guidelines, Treatment Recommendations and Complex Treatment Situations. Pharmacopsychiatry 2014;47:53-59
Licht RW, Straarup KN. [Prophylactic treatment of affective disorders] Ugeskr Laeger. 2007;169:1453-1455 Danish.
Löffler F, van Calker D, Hamprecht B. Parathyrin and calcitonin stimulate cyclic AMP accumulation in cultured murine brain cells. EMBO J. 1982;1(3):297-302
Lubrich B, van Calker D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology. 1999 Oct;21(4):519-29
Minnai GP, Salis P, Manchia M, Pinna M, Tondo L: What happens to the course of bipolar disorder after electroconvulsive therapy? J. Affect. Disord. 2016
Minnai GP, Tondo L, Salis P, Ghiani C, Manfredi A, Paluello MM, Baethge C, Baldessarini RJ: Secular trends in first hospitalizations for major mood disorders with comorbid substance use. Int. J. Neuropsychopharmacol. 2006; 9:319–26
Müller-Oerlinghausen, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002;359:241-247
Nielsen JB, Vestergaard P. [Lithium intoxication: assessment, treatment and prevention] Ugeskr Laeger. 2007;169:522. Danish
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen W a, Grunze H, Licht RW, Post RM, Berk M,
Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom E a, Tohen M, Undurraga J,
González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME,
Koukopoulos A, Colom F, Frye M a, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH,
Ketter T a, Cassidy F, Akiskal H, Azorin J-M, Valentí M, Mazzei DH, Lafer B, Kato T,
Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer
M, Yatham LN, Zarate C a, Nierenberg A a, Birmaher B, Kanba S, El-Mallakh RS, Serretti A,
Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-
Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM,
Kapczinski F, Vieta E: The International Society for Bipolar Disorders (ISBD) task force
report on antidepressant use in bipolar disorders. Am. J. Psychiatry 2013; 170:1249–62
Pfennig A, Bschor T, Falkai P, Bauer M (2013) The diagnosis and treatment of bipolar disorder – recommendations from the current S3 guideline. Dtsch Arztebl Int 110:92-100, DOI: 10.3238/arztebl.2013.0092
Pfennig A, Bschor T, Baghai T, Bräunig P, Brieger P, Falkai P, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Möhrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M. S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations. Nervenarzt. 2012;83:568-86
Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintencance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. J Affect Disord 2010;126:453-457
Rybakowski J, Kiejna A, Nawacka-Pawlaczyk D, Kargul M. [Clinical picture and treatment of subsequent depressive episodes-results of Polish multicenter study] Psychiatr Pol 2003;37:419-431
Sani G, Tondo L, Koukopoulos A, Reginaldi D, Kotzalidis GD, Koukopoulos AE, Manfredi G, Mazzarini L, Pacchiarotti I, Simonetti A, Ambrosi E, Angeletti G, Girardi P, Tatarelli R: Suicide in a large population of former psychiatric inpatients. Psychiatry Clin. Neurosci. 2011; 65:286–95
Rybakowski JK. Lithium: sixty years thereafter. Neuropsychobiology 2010;62:5-7
Schramm E, van Calker D, Dykierek P, Lieb K, Kech S, Zobel I, Leonhart R, Berger M. An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results. Am J Psychiatry. 2007 May;164(5):768-77
Schou M. Lithium treatment at 52. J Affect Disord 2001;67:21-32
Schou M. Suicidal behavior and prophylactic lithium treatment of major mood disorders: A review of reviews. Suicide Life-Threat Behav 2000;10:289-293
Schou M. Perspectives on lithium treatment of bipolar disorder: action, efficacy, effect on suicidal behavior. Bipolar Disord 1999;1:5-10
Schou M. The early European lithium studies. Aust NZ J Psychiatry 1999;33:S39-S47
Schou M. The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians. J Affect Disord 1998;50:253-259
Schou M. Treating recurrent affective disorders during and after pregnancy. What can be taken safely? Drug Saf 1998;18:143-152
Schou M. Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 1998;31:210-215
Schou M. The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand 1997;95:361-363
Schou M. Prophylactic lithium treatment of unipolar and bipolar manic-depressive illness. Psychopathol 1995;28 (Suppl 1):81-85
Schou M. Where shall we put lithium et al? Br J Psychiatry 1995;166:678-679
Schou M. Is there a lithium withdrawal syndrome? An examination of the evidence. Br J Psychiatry. 1993;163:514-518
Schou M. Lithium prophylaxis in perspective. Pharmacopsychiatry 1992;25:7-9
Schou M. The first psychiatric use of lithium. Br J Psychiatry. 1992;161:279-280
Serchov T, Clement HW, Schwarz MK, Iasevoli F, Tosh DK, Idzko M, Jacobson KA, de Bartolomeis A, Normann C, Biber K, van Calker D. Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a. Neuron. 2015 Aug 5;87(3):549-62
Simhandl C, Mersch J. Lithium and bipolar disorder – a renaissance? Neuropsychiatr 2007;21:121-130
Spleiss O, van Calker D, Schärer L, Adamovic K, Berger M, Gebicke-Haerter PJ.Abnormal G protein alpha(s) – and alpha(i2)-subunit mRNA expression in bipolar affective disorder. Mol Psychiatry. 1998 Nov;3(6):512-20
Thomsen K, Schou M. Avoidance of lithium intoxication: Advice based on knowledge about the renal lithium clearance under various circumstances. Pharmacopsychiatry 1999;32:83-86
Tondo L, Vázquez GH, Baethge C, Baronessa C, Bolzani L, Koukopoulos A, Mazzarini L, Murru A, Pacchiarotti I, Pinna M, Salvatore P, Sani G, Selle V, Spalletta G, Girardi P, Tohen M, Vieta E, Baldessarini RJ: Comparison of psychotic bipolar disorder, schizoaffective disorder, and schizophrenia: an international, multisite study. Acta Psychiatr. Scand. 2016; 133:34–43
van Calker D, Zobel I, Dykierek P, Deimel CM, Kech S, Lieb K, Berger M, Schramm E. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord. 2009 Apr;114(1-3):243-53
van Calker D, Müller M, Hamprecht B. Regulation by secretin, vasoactive intestinal peptide, and somatostatin of cyclic AMP accumulation in cultured brain cells. Proc Natl Acad Sci USA. 1980 Nov;77(11):6907-11
van Calker D, Müller M, Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem. 1979; 33(5):999-1005
van Calker, D., Müller, M. & Hamprecht, B. Adenosine inhibits the accumulation of cyclic AMP in cultured brain cells. Nature 1978; 276, 839-841
Vestergaard P, Licht RW. [Preventive drug therapy of depressions] Ugeskr Laeger 2003;165:2191-2194
Vestergaard P, Licht RW. 50 Years with lithium treatment in affective disorders: present problems and priorities. World J Biol Psychiatry 2001;2:18-26
Vieta E, Nolen WA, Grunze H, Licht RW, Goodwin G. A European perspective on the Canadian guidelines for bipolar disorder. Bipolar Disord 2005;7 (Suppl 3):73-76
Yatham LN, Kennedy SH, O’Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, Beaulieu S, Daigneault A, Milev R, Young LT, Ravindran A, Schaffer A, Connolly M, Gorman CP; Canadian Network for Mood and Anxiety Treatments. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7 (Suppl 3):5-69
Young LT. What exactly is a mood stabilizer? J Psychiatry Neurosci 2004;29:87-88
Willmroth F, Drieling T, Lamla U, Marcushen M, Wark HJ, van Calker D. Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers. Int J Neuropsychopharmacol. 2007 Feb;10(1):63-71
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O’Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15: 1-44
Zaninelli R, Bauer M, Jobert M, Müller-Oerlinghausen B. Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. J Clin Psychopharmacol 2001;21:190-198
Albuquerque J, Deshauer D, Grof P. Descartes’ Passions of the soul-seeds of psychiatry? J Affect Disord 2003;76:285-291
Baethge C, Baldessarini RJ, Freudenthal K, Streeruwitz A, Bauer M, Bschor T. Hallucinations in bipolar disorder: characteristics and comparison to unipolar depression and schizophrenia. Bipolar Disord 2005;7:136-145
Baethge C, Salvatore P, Baldessarini RJ. Cyclothymia, a circular mood disorder by Ewald Hecker. Introduction and translation. History of Psychiatry 2003;14:377-399
Baethge C, Salvatore P, Baldessarini RJ. On Cyclic Insanity by Karl Ludwig Kahlbaum, M.D., 1882: Translation and Commentary. Harv Rev Psychiatry 2003;11:78-90
Bauer M, Grof P, Rasgon N, Bschor T, Glenn T, Whybrow PC. Temporal relation between sleep and mood in patients with bipolar disorder. Bipolar Disord 2006;8:160-167
Bschor T, Ising M, Bauer M, Lewitzka U, Skerstupeit M, Mueller-Oerlinghausen B, Baethge C. Time experience and time judgment in major depression, mania and healthy subjects. A controlled study of 93 subjects. Acta Psychiatr Scand 2004;109:222-229
Kiejna A, Rymaszewska J, Suwalska A, Lojko D, Rybakowski J. [The probability of bipolarity among patients with recurrent depressive disorder] Psychiatr Pol. 2006;40:445-454 Polish
Rybakowski F, Rybakowski J. [Evolutionary concepts of affective disorders] Psychiatr Pol 2006;40:401-413
Rybakowski J, Klonowska P, Patrzala A, Jaracz J. [Psychopathology and creativity] Psychiatr Pol 2006;40:1033-1049
Trede K, Salvatore P, Baethge C, Gerhard A, Maggini C, Baldessarini RJ. Manic-depressive illness: evolution in Kraepelin’s Textbook, 1883-1926. Harv Rev Psychiatry 2005;13:155-178
Angst J, Gamma A, Neuenschwander M, Ajdacic-Gross V, Eich D, Rossler W, Merikangas KR. Prevalence of mental disorders in the Zurich Cohort Study: a twenty year prospective study. Epidemiol Psichiatr Soc 2005;14:68-76
Baethge C, Tondo L, Bratti IM, Bschor T, Bauer M, Viguera AC, Baldessarini RJ: Prophylaxis latency and outcome in bipolar disorders. Can. J. Psychiatry. 2003; 48:449–57
Baldassano CF, Marangell LB, Gyulai L, Nassir Ghaemi S, Joffe H, Kim DR, Sagduyu K, Truman CJ, Wisniewski SR, Sachs GS, Cohen LS. Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. Bipolar Disord 2005;7:465-470
Bauer M, Pfennig A. Epidemiology of bipolar disorders. Epilepsia 2005;46 (Suppl 4):8-13
Bauer M, Rasgon N, Grof P, Altshuler L, Gyulai L, Lapp M, Glenn T, Whybrow PC. Mood changes related to antidepressants: a longitudinal study of patients with bipolar disorder in a naturalistic setting. Psychiatry Res 2005;133:73-80
Bschor T, Angst J, Azorin JM, Bowden CL, Perugi G, Vieta E, Young AH, Krüger S. Are bipolar disorders underdiagnosed in patients with depressive episodes? Results of the multicenter BRIDGE screening study in Germany. J Affect Disord 2012;142:45-52
Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, O’Donovan MC, Alda M. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry 2015; 206: 52-57.
Hajek T, Slaney C, Garnham J, Ruzickova M, Passmore M, Alda M. Clinical correlates of current level of functioning in primary care-treated bipolar patients. Bipolar Disord 2005;7:286-291
Hecht H, Genzwurker S, Helle M, van Calker D. Social functioning and personality of subjects at familial risk for affective disorder. J Affect Disord 2005;84:33-42
Laursen TM, Labouriau R, Licht RW, Bertelsen A, Munk-Olsen T, Mortensen PB. Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. Arch Gen Psychiatry 2005;62:841-848
Minnai GP, Tondo L, Salis P, Ghiani C, Manfredi A, Paluello MM, Baethge C, Baldessarini RJ. Secular trends in first hospitalizations for major mood disorders with comorbid substance use. Int J Neuropsychopharmacol 2005; 1-8
Ogendahl BK, Agerbo E, Byrne M, Licht RW, Eaton WW, Mortensen PB. Indicators of fetal growth and bipolar disorder: a Danish national register-based study. Psychol Med 2006;36:1219-1224
Rasgon N, Bauer M, Grof P, Gyulai L, Elman S, Glenn T, Whybrow PC. Sex-specific self-reported mood changes by patients with bipolar disorder. J Psychiatr Res 2005;39:77-83
Rybakowski JK, Suwalska A, Lojko D, Rymaszewska J, Kiejna A. Bipolar mood disorders among Polish psychiatric outpatients treated for major depression. J Affect Disord 2005;84:141-147
Sajatovic M, Gyulai L, Calabrese JR, Thompson TR, Wilson BG, White R, Evoniuk G. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry 2005;13:305-311
Deshauer D, Fergusson D, Duffy A, Albuquerque J, Grof P. Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect. Bipolar Disord 2005;7:382-387
Licht RW, Qvitzau S, Allerup P, Bech P. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005;111:144-149
Revicki DA, Hanlon J, Martin S, Gyulai L, Nassir Ghaemi S, Lynch F, Mannix S, Kleinman L. Patient-based utilities for bipolar disorder-related health states. J Affect Disord 2005;87:203-210
Amsterdam JD, Maislin G, Rybakowski J. A possible antiviral action of lithium carbonate in herpes simplex virus infections. Biol Psychiatry 1990;27:447-453
Bschor T. Complete suppression of recurrent herpes labialis with lithium carbonate. Pharmacopsychiat 1999;32:158
Rybakowski JK. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry. 2000;33:159-164
© 2025 Igsli – Designet af Aveo web&marketing
